With solid Q2, Sanofi CEO says M&A could be part of growth strategy

Eric Palmer

's new CEO, Olivier Brandicourt, has a new company structure he is trotting out, a new potentially hot cholesterol-lowering drug to launch and now is able to take credit for a full quarter's worth of financial results that outperformed the street's best guesses. He even said today that may be ready to do some wheeling and dealing, having so far stayed out of the M&A melee that has been going on all year.

FiercePharma News

Share This Post

Related Articles

Leave a Reply

© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS